TCGA-CR-5249-01A-01R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.320
- ALLOGRAFT_REJECTION+0.290
- SPERMATOGENESIS+0.280
- IL6_JAK_STAT3_SIGNALING+0.210
- MITOTIC_SPINDLE+0.210
- ANDROGEN_RESPONSE+0.190
- HEDGEHOG_SIGNALING+0.190
- INFLAMMATORY_RESPONSE+0.190
- WNT_BETA_CATENIN_SIGNALING+0.180
- G2M_CHECKPOINT+0.170
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- OXIDATIVE_PHOSPHORYLATION-0.530
- MYC_TARGETS_V1-0.520
- ANGIOGENESIS-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- INTERFERON_ALPHA_RESPONSE-0.380
- DNA_REPAIR-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- MYOGENESIS-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5153-01A-01R-1436-07 | — | — | 0.803 |
| 2 | SRR17866851 | — | — | 0.733 |
| 3 | TCGA-CV-6939-01A-11R-1915-07 | — | — | 0.731 |
| 4 | TCGA-CR-7368-01A-11R-2132-07 | — | — | 0.728 |
| 5 | TCGA-CR-5250-01A-01R-1514-07 | — | — | 0.720 |
| 6 | MNG255 | — | — | 0.720 |
| 7 | TCGA-XF-AAN0-01A-11R-A42T-07 | — | — | 0.708 |
| 8 | 4b4a3828-d808-4d25-a06c-b738fd8daacb | — | — | 0.707 |
| 9 | TCGA-CR-5243-01A-01R-1514-07 | — | — | 0.694 |
| 10 | MNG34 | — | — | 0.686 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |